Affiliation:
1. Clinical Pharmacology, Faculty of Medical Science, University of Kragujevac , Kragujevac , Serbia
2. Pharmacology and Toxicology Department, Faculty of Medical Sciences, University of Kragujevac , Kragujevac , Serbia
Abstract
Abstract
Although being very effective in the treatment of diabetes and a few other conditions, metformin (MTF) cannot be tolerated by many patients due to gastrointestinal (GI) complaints. A number of risk factors for intolerance were identified, but many are still controversial or uninvestigated. The aim of this study was to further investigate possible risk factors for the occurrence of GI complaints in patients on MTF therapy. A cross-sectional design was used for this multicentric study on adult patients visiting 50 community pharmacies in Montenegro. The patients were surveyed by semi-structured questionnaire after a service of a pharmacist was delivered, and their drugs dispensed. Uni- and multi-variate regression methods were used for processing the data.
In total 330 patients participated in the study. A higher body mass index (OR = 1.113, p = 0.003), living at a higher altitude (OR = 1.725, p = 0.000), anaemia (OR = 4.221, p = 0.008), and intestinal infection in the last 3 months (OR = 2.801, p = 0.006) increased the risk of GI complaints in patients on MTF therapy, while the use of statins was protective (OR = 0.204, p = 0.016). Each case of MTF intolerance should be carefully investigated for risk and protective factors, which could be potentially eliminated or augmented, respectively, and MTF withdrawal avoided.
Reference32 articles.
1. Kaneto H, Kimura T, Obata A, Shimoda M, Kaku K. Multifaceted mechanisms of action of metformin which have been unraveled one after another in the long history. Int J Mol Sci. 2021;22(5):2596.
2. Lv Z, Guo Y. Metformin and its benefits for various diseases. Front Endocrinol. 2020;11:191.
3. Committee for Proprietary Medicinal Products (CPMP/4082/00). Summary information on a referral opinion following an arbitration pursuant to article 11 of council directive 75/319/EEC as amended, for Glucophage/Glucophage forte/Risidon/Dianben. Vol. 16. London: International Nonproprietary Name (INN) Metformin; 2001.
4. Fatima M, Sadeeqa S, Nazir SUR. Metformin and its gastrointestinal problems: A review. Biomed Res. 2018;29(11):2285–9.
5. Saluja M, Pareek KK, Swami YK. Study of diversity of metformin related gastrointestinal side effects. J Assoc Physicians India. 2020;68(8):36–8.